DB05180InvestigationalSmall molecule
LX6171 is an oral drug candidate that was generated by Lexicon medicinal chemists and is being developed to treat disorders characterized by cognitive impairment, such as Alzheimer's disease, schizophrenia or...
- Mechanism
- Curator reviewed
The target of LX6171 is a membrane protein that is expressed exclusively in the central nervous system. Its activity is associated with synaptic vesicles and presynaptic membranes.
- Primary indication
- Investigated for use/treatment in alzheimer's disease, attention deficit/hyperactivity disorder (ADHD), dementia, neurologic disorders, and schizophrenia and schizoaffective disorders.Curator reviewed
- Code names
- LX6171
Resolves to
Compound
What you can answer from here — as of April 02, 2025
Which companies are running trials of LX6171, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account